These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37032119)

  • 21. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Potential application of sofosbuvir-based treatment for chronic hepatitis C in China].
    Zhang QF; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):233-237. PubMed ID: 29804397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Chung W; Kim KA; Jang ES; Ki M; Choi HY; Jeong SH
    J Gastroenterol Hepatol; 2019 Apr; 34(4):776-783. PubMed ID: 30462841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
    Bernhard B; Stickel F
    Z Gastroenterol; 2020 May; 58(5):451-455. PubMed ID: 32392606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
    Garrison KL; German P; Mogalian E; Mathias A
    Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
    Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
    J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 May; 36(5):651-8. PubMed ID: 26616353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.
    Sun HY; Cheng CY; Lin CY; Yang CJ; Lee NY; Liou BH; Tang HJ; Liu YM; Lee CY; Chen TC; Huang YC; Lee YT; Tsai MJ; Lu PL; Tsai HC; Wang NC; Hung TC; Cheng SH; Hung CC
    World J Gastroenterol; 2022 Mar; 28(11):1172-1183. PubMed ID: 35431505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct antiviral treatment of chronic hepatitis C in heart transplant recipients.
    Vitrone M; Andini R; Mattucci I; Maiello C; Atripaldi L; Durante-Mangoni E; Zampino R
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29139181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    Ahn SH; Lim YS; Lee KS; Paik SW; Lee YJ; Jeong SH; Kim JH; Yoon SK; Yim HJ; Tak WY; Han SY; Yang JC; Mo H; Mathias A; Han L; Knox SJ; Brainard DM; Kim YJ; Byun KS; Kim YS; Heo J; Han KH
    J Viral Hepat; 2016 May; 23(5):358-65. PubMed ID: 26864153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
    Smolders EJ; Smit C; T M M de Kanter C; Dofferiiof ASM; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):193-199. PubMed ID: 28902678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
    Onofrio FQ; Cooper C; Borgia SM; Vachon ML; Ramji A; Lilly LB; Wong A; Booth J; Sattar I; Morales H; Lee S; Conway B; Feld JJ
    Clin Infect Dis; 2021 Jun; 72(11):e799-e805. PubMed ID: 33677545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
    Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
    J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of chronic hepatitis C genotype and evaluation of clinical factors affecting direct-acting antiviral treatment responses in the Western Black Sea Region, Turkey.
    Gok Sargin Z; Dusunceli I
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7256-7262. PubMed ID: 36263536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.
    Ho SB; Monto A; Peyton A; Kaplan DE; Byrne S; Moon S; Copans A; Rossaro L; Roy A; Le H; Dvory-Sobol H; Zhu Y; Brainard DM; Guyer W; Shaikh O; Fuchs M; Morgan TR;
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):282-288. PubMed ID: 27237429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients.
    Liu YC; Jeng WJ; Cheng YT; Hsieh YC; Teng W; Chen YC; Lin CY; Chien RN; Sheen IS
    Medicine (Baltimore); 2020 Sep; 99(37):e21898. PubMed ID: 32925725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
    Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
    Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.
    Lim YS; Ahn SH; Lee KS; Paik SW; Lee YJ; Jeong SH; Kim JH; Yoon SK; Yim HJ; Tak WY; Han SY; Yang JC; Mo H; Garrison KL; Gao B; Knox SJ; Pang PS; Kim YJ; Byun KS; Kim YS; Heo J; Han KH
    Hepatol Int; 2016 Nov; 10(6):947-955. PubMed ID: 27198664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.
    Choi IS; Kim KM; Shim SG
    Arab J Gastroenterol; 2021 Mar; 22(1):23-27. PubMed ID: 33223391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.